MCAD deficiency may be a difficult disease to manage, but with early diagnosis and intervention, this population may avoid life-threatening sequelae during times of illness. Newborn blood screening is highly sensitive and specific for the initial assessment of MCAD deficiency and is an essential screening tool. [Level 3] Further diagnostics using genetic tests (assessing for severe mutations i.e., 985A→G) and biochemical tests (elevation of C8/C10:1) are used to confirm the diagnosis. [Level 3]